Abstract
Purpose Pathogenic variants in GABRB3 have been associated with a spectrum of phenotypes from severe developmental disorders and epileptic encephalopathies to milder epilepsy syndromes and mild intellectual disability. In the present study, we analyzed a large cohort of individuals with GABRB3 variants to deepen the phenotypic understanding and investigate genotype-phenotype correlations.
Methods Through an international collaboration, we analyzed electro-clinical data of unpublished individuals with variants in GABRB3 and we reviewed previously published cases. All missense variants were mapped onto the 3D structure of the GABRB3 subunit and clinical phenotypes associated with the different key structural domains were investigated.
Results We characterize 71 individuals with GABRB3 variants, including 22 novel subjects, expressing a wide spectrum of phenotypes. Interestingly, phenotypes correlated with structural locations of the variants. Generalized epilepsy, with a median age at onset of 10.5 months, and mild-to-moderate intellectual disability were associated with variants in the extracellular domain. Focal epilepsy with early onset (median: 2.75 months of age) and severe intellectual disability were associated with variants in the pore-lining helical transmembrane domain.
Conclusion These genotype/phenotype correlations will aid the genetic counseling and treatment of individuals affected by GABRB3-related disorders. Future studies may reveal whether functional differences underlie the phenotypic differences.
Key points
Pathogenic variants in GABRB3 cause a wide range of phenotypes
Missense variants in the ECD have generalized epilepsy with later onset and non-severe ID
Missense variants in the TMD have focal epilepsy with early onset and severe ID
Behavioral issues are common features of GABRB3 disease
Precision medicine approaches for GABRB3 disease is limited
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Novo Nordisk Foundation (NNF19OC0058749 to RSM), the Agencia Nacional de Investigacion y Desarrollo (ANID, PAI77200124 to EP) of Chile and the FamilieSCN2A foundation 2020 Action Potential Grant (to EP). PS worked within the framework of the DINOGMI Department of Excellence of MIUR 2018-2022 (legge 232 del 2016).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All institutions involved in human participant research received local IRB approval (main IRB: The ethics committee of Region Zealand, Denmark). Written informed consent, including authorization for reproduction of video images, was obtained for all individuals (or legal guardians) and family members where necessary. Individual data were collected according to local ethics committee guidelines.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of interest The authors of this paper declare that they have no conflicts of interest.
Data Availability
De-identified data will be made available to those eligible. Data includes the GABRB3 database and data used for 3D analysis including statistical logging. Data will be stored for six months.